Related Experiment Videos
Psychological support and psychiatric management of patients with automatic implantable cardioverter defibrillators
P J Tchou1, E Piasecki, M Gutmann
1University of Wisconsin Medical School, Milwaukee Clinical Campus.
Insights
Automatic implantable cardioverter defibrillators (AICD) reduce mortality in high-risk patients. However, AICD recipients with cardiac disease need psychological support and careful monitoring of psychotropic medications and electroconvulsive therapy due to potential risks.
Area of Science:
- Cardiology
- Psychiatry
- Medical Device Technology
Background:
- Over 6,000 automatic implantable cardioverter defibrillators (AICD) implanted since 1980.
- AICDs effectively reduce mortality from arrhythmias in high-risk individuals.
- Common comorbidities in AICD patients include coronary artery disease and prior myocardial infarctions.
Purpose of the Study:
- To highlight the psychosocial stresses experienced by AICD patients with cardiac disease.
- To emphasize the need for psychological support and psychiatric treatment in this population.
- To underscore precautions for psychotropic medication use and electroconvulsive therapy in AICD patients.
Main Methods:
- Review of existing literature on AICD implantation and patient outcomes.
- Analysis of psychological comorbidities in patients with cardiac disease and AICDs.
- Evaluation of potential drug-drug interactions and treatment risks.
Main Results:
- AICD patients with cardiac conditions are vulnerable to depression and psychological disturbances.
- Certain psychotropic medications can exacerbate ventricular tachyarrhythmias.
- Electroconvulsive therapy requires specific safety considerations in this patient group.
Conclusions:
- Comprehensive psychological support is crucial for AICD patients with cardiac disease.
- Close monitoring of psychotropic drug use is essential to prevent adverse cardiac events.
- Special precautions are necessary when considering electroconvulsive therapy for these patients.
Abstract:
There are well over 6,000 automatic implantable cardioverter defibrillators (AICD) that have been implanted in the United States since 1980. The device clearly reduces arrhythmic mortality in high risk patients. Many AICD patients have other cardiac diseases, most commonly, coronary artery disease with associated prior myocardial infarctions. These patients have special psychosocial stresses that may make them vulnerable to depression and other psychological disturbances. Psychological support together with psychiatric treatment, if needed, should be provided to these patients. Use of psychotropic medications should be closely monitored, especially in this population, as many of these drugs can exacerbate ventricular tachyarrhythmias. Special precautions should also be taken when administering electroconvulsive therapy in these patients.